Safety and efficacy of left atrial appendage closure combined with patent foramen ovale closure for atrial fibrillation patients with patent foramen ovale.
10.3760/cma.j.cn112148-20211214-01073
- Author:
Zhi Hong ZHAO
1
;
Xiang SONG
1
;
Sai Hua WANG
1
;
Jun LUO
1
;
Ying Biao WU
1
;
Qian ZHU
1
;
Ming FANG
1
;
Qiang HUAN
1
;
Xiao Gang ZHANG
1
;
Bei TIAN
1
;
Wei GU
1
;
Luo Ning ZHU
1
;
Shu Wen HAO
1
;
Zhong Ping NING
1
Author Information
1. Department of Cardiology, Zhoupu Hospital, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Atrial Appendage/surgery*;
Atrial Fibrillation/surgery*;
Cardiac Catheterization/methods*;
China;
Cross-Sectional Studies;
Foramen Ovale, Patent/surgery*;
Humans;
Male;
Middle Aged;
Retrospective Studies
- From:
Chinese Journal of Cardiology
2022;50(3):257-262
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the safety and efficacy of combined left atrial appendage (LAA) and patent foramen ovale (PFO) closure in adult atrial fibrillation (AF) patients complicating with PFO. Methods: This study is a retrospective and cross-sectional study. Seven patients with AF complicated with PFO diagnosed by transesophageal echocardiography (TEE) in Zhoupu Hospital Affiliated to Shanghai University of Medicine & Health Sciences from June 2017 to October 2020 were selected. Basic data such as age, gender and medical history were collected. The atrial septal defect or PFO occluder and LAA occluder were selected according to the size of PFO, the ostia width and depth of LAA. Four patients underwent left atrial appendage closure(LAAC) and PFO closure at the same time. PFO closure was performed during a one-stop procedure of cryoablation combined with LAAC in 2 patients. One patient underwent PFO closure at 10 weeks after one-stop procedure because of recurrent transient ischemic attack (TIA). All patients continued to take oral anticoagulants. TEE was repeated 8-12 weeks after intervention. In case of device related thrombus(DRT), TEE shall be rechecked 6 months after adjusting anticoagulant and antiplatelet drug treatment. Patients were follow-up at 1, 3, 6, 12, 24 months by telephone call, and the occurrence of cardio-cerebrovascular events was recorded. Results: Among the 7 patients with AF, 2 were male, aged (68.0±9.4) years, and 3 had a history of recurrent cerebral infarction and TIA. Average PFO diameter was (3.5±0.8)mm. Three patients were implanted with Watchman LAA occluder (30, 30, 33 mm) and atrial septal defect occluder (8, 9, 16 mm). 2 patients were implanted with LAmbre LAA occluder (34/38, 18/32 mm) and PFO occluder (PF1825, PF2525). 2 patients were implanted with LACbes LAA occluder (24, 28 mm) and PFO occluder (PF2525, PF1825) respectively. The patients were followed up for 12 (11, 24) months after operation. TEE reexamination showed that the position of LAA occluder and atrial septal defect occluder or PFO occluder was normal in all patients. DRT was detected in 1 patient, and anticoagulant therapy was adjusted in this patient. 6 months later, TEE showed that DRT disappeared. No cardiovascular and cerebrovascular events occurred in all patients with AF during follow-up. Conclusions: In AF patients complicated with PFO, LAAC combined with PFO closure may have good safety and effectiveness.
